CDD3506 can increase high-density lipoprotein cholesterol (HDL) levels by inducing hepatic CYP3A activity.

Physicochemical Properties

Molecular Formula	C22H19N3
Molecular Weight	325.4064
Exact Mass	325.157
CAS #	197913-15-8
PubChem CID	9862108
Appearance	Light brown to brown solid powder
Density	1.1±0.1 g/cm3
Boiling Point	506.4±45.0 °C at 760 mmHg
Flash Point	260.1±28.7 °C
Vapour Pressure	0.0±1.3 mmHg at 25°C
Index of Refraction	1.629
LogP	2.86
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	2
Rotatable Bond Count	4
Heavy Atom Count	25
Complexity	360
Defined Atom Stereocenter Count	0
InChi Key	RCJCNSQHHMJLRL-UHFFFAOYSA-N
InChi Code	InChI=1S/C22H19N3/c23-21-16-25(17-24-21)22(18-10-4-1-5-11-18,19-12-6-2-7-13-19)20-14-8-3-9-15-20/h1-17H,23H2
Chemical Name	1-tritylimidazol-4-amine
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	Cytochrome P450 3A (CYP3A, hepatic) [1]
ln Vitro	CDD3506 specifically activates hepatic cytochrome P450IIIA and dramatically raises HDL cholesterol [1].
References	[1]. Method for increasing HDL cholesterol levels?using?heteroaromatic phenylmethanes. United States Patent 6103733.

Solubility Data

Solubility (In Vitro)

DMSO : ~19 mg/mL (~58.39 mM)

Solubility (In Vivo)

Solubility in Formulation 1: 1.9 mg/mL (5.84 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 19.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.9 mg/mL (5.84 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 19.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.0730 mL	15.3652 mL	30.7305 mL
	5 mM	0.6146 mL	3.0730 mL	6.1461 mL
	10 mM	0.3073 mL	1.5365 mL	3.0730 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.